Renal Cell Carcinoma
Conference Coverage
Cabozantinib boosts dual immunotherapy in advanced RCC
The new study suggests triplet therapy may become a new standard of care in advanced renal cell carcinoma.
From the Journals
Checkpoint inhibitor combos show promise in advanced RCC
Authors of a systematic review suggest the combinations should be widely available as first-line treatment.
Feature
Getting cancer research on track again may require a ‘behemoth’ effort
Cancer Moonshot aims to cut cancer-related deaths in half, but funding and pandemic challenges may hinder progress.
From the Journals
Immuno-oncology combos show promise in renal cell cancer
But review finds that long-term prognostic evidence is still lacking.
From the Journals
Targeted therapy for renal cell cancer linked to higher cardiac risk
Risk of major events nearly doubled in patients on targeted drugs vs. cytokine therapy.
From the Journals
Immune checkpoint and VEGF inhibitors superior in renal cell carcinoma treatment
This combination treatment led to longer overall survival than with doublet immune checkpoint blockade.
From the Journals
Analysis shows no benefit for cytoreductive nephrectomy
Observational studies of metastatic clear cell renal cell carcinoma fail to adjust for bias.
From the Journals
Quality of life benefit exaggerated in some cancer studies
From the Journals
ASCO outlines optimal treatments for patients with metastatic clear cell renal cell carcinoma
A dramatic increase in therapy options prompted the first guidance issued by ASCO earlier this year.
Latest News
First-line nivolumab monotherapy effective in some kidney cancers
A phase 2 trial found high response rates in patients classified as favorable risk and more widespread PD-L1 expression.